July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Comparison between several optical coherence tomography angiography devices and indocyanine green angiography of choroidal neovascularization
Author Affiliations & Notes
  • Federico Corvi
    Ophthalmology, Luigi Sacco Hospital University of Milan, Milan, Italy
  • Mariano Cozzi
    Ophthalmology, Luigi Sacco Hospital University of Milan, Milan, Italy
  • Maria Belotti
    Ophthalmology, Luigi Sacco Hospital University of Milan, Milan, Italy
  • Dario Nizza
    Ophthalmology, Luigi Sacco Hospital University of Milan, Milan, Italy
  • Giovanni Staurenghi
    Ophthalmology, Luigi Sacco Hospital University of Milan, Milan, Italy
  • Andrea Giani
    Ophthalmology, Luigi Sacco Hospital University of Milan, Milan, Italy
  • Footnotes
    Commercial Relationships   Federico Corvi, None; Mariano Cozzi, None; Maria Belotti, None; Dario Nizza, None; Giovanni Staurenghi, Alcon (C), Allergan (C), Bayer (C), Boheringer (C), Carl Zeiss Meditec (C), Centervue (C), Genentech (C), GSK (C), Heidelberg Engineering (C), Medical (C), Novartis (C), Ocular Instruments (P), Quantel (C), Roche (C); Andrea Giani, Boheringer (C), ERA (C), Grandvision (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4551. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Federico Corvi, Mariano Cozzi, Maria Belotti, Dario Nizza, Giovanni Staurenghi, Andrea Giani; Comparison between several optical coherence tomography angiography devices and indocyanine green angiography of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4551.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare indocyanine green angiography (ICGA) and 4 different optical coherence tomography angiography (OCTA) devices and to test their reproducibility in the evaluation of choroidal neovascularization (CNV).

Methods : Observational case series of Type 1 and Type 2 CNV presenting at the Eye Clinic, Department of Biomedical and Clinical Sciences, Luigi Sacco Hospital, University of Milan imaged with ICGA and 4 different OCTA: prototype PlexElite (Carl Zeiss Meditec), prototype Spectralis OCTA (Spectralis; Heidelberg Engineering, Heidelberg, Germany), Optovue RTVue XR Avanti (Optovue, Inc, Fremont, California, USA) and AngioPlex (Cirrus 5000 HD-OCT; Carl Zeiss Meditec, Inc, Dublin, California, USA). OCTA examinations were performed using a 3 x 3 mm or 6 x 6 mm volume scan pattern in order to capture the full lesion. The mean area of CNV, vessel density (VD) and fractal dimension (FD) were compared between devices.

Results : A total of 17 eyes of 17 patients with CNV were enrolled in this study. The mean age was 74.7 ± 13.7 years with 13 male and 4 female patients. The mean BCVA was 20/70 (range, 20/200-20/20) with 13 eyes treatment naïve and 4 eyes had received prior intravitreal therapy with VEGF inhibitors. Nine eyes presented a type 1 CNV and 8 eyes a type 2 CNV. The CNV area was significantly larger in ICGA then OCTA devices. Moreover, the 4 different instruments produced measurements with different mean values of CNV area, VD and FD. Bland-Altman analysis revealed that the limits of agreement for the comparisons were not acceptable.

Conclusions : CNV area is larger when imaged with standard ICGA compared to different OCTA devices with different algorithm, wavelength and scan pattern. The differences between several OCTA devices in the evaluation of quantitative parameters of CNV, as CNV area, VD and FD, suggests the necessity to standardize OCTA measurements for research and clinical practice

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×